MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
CAS No. : 1216941-48-8
MCE 国际站:Paritaprevir
产品活性:Paritaprevir (ABT-450) 是一种有效且具有口服活性和抗病毒活性的非结构蛋白 3/4A (NS3/4A) 蛋白酶抑制剂,对 HCV 1a 和 1b 的 EC50 分别为 1 和 0.21 nM。Paritaprevir 也是一种 SARS-CoV 3CLpro 抑制剂,IC50 为1.31 μM。Paritaprevir 主要由细胞色素 P450 (CYP) 3A 代谢。利托那韦 (Ritonavir,一种 CYP450 抑制剂) 可提高 Paritaprevir 的血浆浓度和半衰期。
研究领域:Metabolic Enzyme/Protease | Anti-infection
作用靶点:HCV Protease | HCV | SARS-CoV
In Vitro: Paritaprevir has in vitro antiviral activity against HCV GT1-4 and GT6 (EC50 range, 0.09 to 19 nM), with an EC50 of 0.09 nM against GT4a.
In Vivo: The combination of Paritaprevir, Ritonavir, Ombitasvir (an NS5A protein inhibitor), and Dasabuvir (an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections.
The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: Cmax 1.82 μg/mL, AUC0-24 8.89 μg·h/mL; dog 100 mg/kg, mean: Cmax 61.3 μg/mL, AUC0-24 285 μg·h/mL).
相关产品:Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Antiviral Compound Library | Drug Repurposing Compound Library | Macrocyclic Compound Library | NMPA-Approved Drug Library | Orally Active Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Hepatitis C Virus Compound Library | EMA-Approved Drug Library | Heterocyclic Compound Library | Withdrawn Drug Compound Library | Sofosbuvir impurity J | Alisporivir | Antimicrobial agent-10 | GS-9256 | SARS-CoV-2-IN-23 | PSI-7409 tetrasodium | 3CPLro-IN-1 | Dasabuvir | FNC-TP | DDX3-IN-1 | SP inhibitor 1 | rel-Zotatifin | Monodes(N-carboxymethyl)valine Daclatasvir | Antioxidant agent-9 | Regdanvimab | Silymarin | NHC-triphosphate tetraammonium | Sofosbuvir-d6 | Grazoprevir potassium salt | Atazanavir | Daclatasvir-d16 | FWM-4 | Amantadine-d6 | Deferiprone | Ketotifen fumarate | Dehydrojuncusol | Daclatasvir dihydrochloride | SARS-CoV-2-IN-27 | Ribavirin | MMT5-14
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸 | 抗体 | 点击化学
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides | Antibodies | Click Chemistry
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库,我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物;
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领;
• 产品种类涵盖各种重组蛋白,多肽,常用试剂盒 ,更有 PROTAC、ADC 等特色产品,广泛应用于新药研发、生命科学等科研项目;
• 提供虚拟筛选,离子通道筛选,代谢组学分析检测分析,药物筛选等专业技术服务;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果;
• 专业团队跟踪最新的制药及生命科学研究进展,为您提供全球最新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。